ID   CHO/CD44s
AC   CVCL_D2R9
RX   PubMed=35628345;
RX   PubMed=36835416;
RX   PubMed=36975491;
RX   PubMed=37176118;
RX   PubMed=37185762;
RX   PubMed=37218897;
RX   PubMed=37504249;
CC   Transfected with: HGNC; 1681; CD44 (isoform s with a N-terminal GLEGGVAMPGAEDDVV = PA16-tag).
CC   Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
CC   Cell type: Epithelial cell of ovary; CL=CL_2000064.
OX   NCBI_TaxID=10029; ! Cricetulus griseus (Chinese hamster)
HI   CVCL_0214 ! CHO-K1
SX   Female
AG   Adult
CA   Spontaneously immortalized cell line
DT   Created: 30-01-24; Last updated: 30-01-24; Version: 1
//
RX   PubMed=35628345; DOI=10.3390/ijms23105535;
RA   Goto N., Suzuki H., Tanaka T., Asano T., Kaneko M.K., Kato Y.;
RT   "Development of a novel anti-CD44 monoclonal antibody for multiple
RT   applications against esophageal squamous cell carcinomas.";
RL   Int. J. Mol. Sci. 23:5535.1-5535.15(2022).
//
RX   PubMed=36835416; DOI=10.3390/ijms24044007;
RA   Ejima R., Suzuki H., Tanaka T., Asano T., Kaneko M.K., Kato Y.;
RT   "Development of a novel anti-CD44 variant 6 monoclonal antibody
RT   C44Mab-9 for multiple applications against colorectal carcinomas.";
RL   Int. J. Mol. Sci. 24:4007.1-4007.16(2023).
//
RX   PubMed=36975491; DOI=10.3390/cimb45030121;
RA   Suzuki H., Tanaka T., Goto N., Kaneko M.K., Kato Y.;
RT   "Development of a novel anti-CD44 variant 4 monoclonal antibody
RT   C44Mab-108 for immunohistochemistry.";
RL   Curr. Issues Mol. Biol. 45:1875-1888(2023).
//
RX   PubMed=37176118; DOI=10.3390/ijms24098411;
RA   Suzuki H., Kitamura K., Goto N., Ishikawa K., Ouchida T., Tanaka T.,
RA   Kaneko M.K., Kato Y.;
RT   "A novel anti-CD44 variant 3 monoclonal antibody C44Mab-6 was
RT   established for multiple applications.";
RL   Int. J. Mol. Sci. 24:8411.1-8411.17(2023).
//
RX   PubMed=37185762; DOI=10.3390/cimb45040238;
RA   Tawara M., Suzuki H., Goto N., Tanaka T., Kaneko M.K., Kato Y.;
RT   "A novel anti-CD44 variant 9 monoclonal antibody C44Mab-1 Was
RT   developed for immunohistochemical analyses against colorectal
RT   cancers.";
RL   Curr. Issues Mol. Biol. 45:3658-3673(2023).
//
RX   PubMed=37218897; DOI=10.3390/antib12020031;
RA   Kudo Y., Suzuki H., Tanaka T., Kaneko M.K., Kato Y.;
RT   "Development of a novel anti-CD44 variant 5 monoclonal antibody
RT   C44Mab-3 for multiple applications against pancreatic carcinomas.";
RL   Antibodies 12:31.1-31.16(2023).
//
RX   PubMed=37504249; DOI=10.3390/cimb45070333;
RA   Ishikawa K., Suzuki H., Kaneko M.K., Kato Y.;
RT   "Establishment of a novel anti-CD44 variant 10 monoclonal antibody
RT   C44Mab-18 for immunohistochemical analysis against oral squamous
RT   cell carcinomas.";
RL   Curr. Issues Mol. Biol. 45:5248-5262(2023).
//